Abstract
Background and purpose:
Platelet-rich thrombi are resistant to thrombolytics. Matrix metalloproteinases (MMPs) may be involved in platelet aggregation and contribute to thrombolysis failure in stroke patients.
Methods:
Plasma samples from 23 stroke patients who had received thrombolytics and from 47 healthy volunteers were examined for MMP-2 and MMP-9 by both enzyme-linked immunosorbent assays and zymography.
Results:
The arteries were recanalized in 15 patients but not in the other 8. The MMP-9 plasma level was significantly higher in patients whose arteries were not recanalized.
Conclusions:
MMP-9 may be associated with the formation of a thrombolytics-resistant thrombus.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adult
-
Aged
-
Aged, 80 and over
-
Cerebral Hemorrhage / blood
-
Cerebral Hemorrhage / enzymology
-
Drug Administration Routes
-
Drug Resistance
-
Female
-
Humans
-
Male
-
Matrix Metalloproteinase 2 / blood
-
Matrix Metalloproteinase 9 / blood*
-
Middle Aged
-
Predictive Value of Tests
-
Prospective Studies
-
Reference Values
-
Risk Factors
-
Stroke / blood
-
Stroke / enzymology*
-
Stroke / therapy
-
Thrombolytic Therapy*
-
Tissue Plasminogen Activator / administration & dosage
-
Treatment Failure
-
Treatment Outcome
-
Urokinase-Type Plasminogen Activator / administration & dosage
-
Vascular Patency / drug effects
Substances
-
Tissue Plasminogen Activator
-
Urokinase-Type Plasminogen Activator
-
Matrix Metalloproteinase 2
-
Matrix Metalloproteinase 9